TAVI May Improve Cognitive Function in Patients with Prior Deterioration

This work studies cognitive evolution after transcatheter aortic valve implantation (TAVI). Previous smaller studies reported conflicting results on cognitive function after TAVI.   This study prospectively included 229 patients who were ≥70 years old, had undergone TAVI and were assessed using the Mini Mental State Examination before and 6 months after the procedure. Cognitive deterioration or improvement was<a href="https://solaci.org/en/2016/10/25/tavi-may-improve-cognitive-function-in-patients-with-prior-deterioration/" title="Read more" >...</a>

Cerebral Protection in TAVR: Studies Presented at London Valves

SENTINEL One of the new devices assessed at London Valves was Sentinel, which is made up of two independent filters. The larger filter is deployed in the brachiocephalic trunk, and the smaller filter is deployed in the left common carotid artery. The study included 22 patients and the device was deployed successfully in 20 of them<a href="https://solaci.org/en/2016/10/20/cerebral-protection-in-tavr-studies-presented-at-london-valves/" title="Read more" >...</a>

bivalirudina heparina eventos cardiovasculares adversos

Cardiovascular Events Reduction: Bivalirudin or Heparin?

The MATRIX study did not find a clear advantage of bivalirudin over unfractioned heparin to reduce major adverse cardiovascular events (MACE) or net cardiovascular adverse events (NCAE) in patients undergoing acute coronary syndrome receiving PCI.   This new analyzis confirms there is no difference in ischemic and thrombotic events in patients with acute coronary syndrome<a href="https://solaci.org/en/2016/10/19/cardiovascular-events-reduction-bivalirudin-or-heparin/" title="Read more" >...</a>

How to Make Radial Access Even Safer with Minimum Effort

Courtesy of Dr. Agustín Vecchia.   Since 1990, radial access has progressively gained ground, currently becoming the default technique in most endovascular intervention centers.   One of its few associated complications is radial artery occlusion. While most frequently clinically silent and non-serious, this complication could hinder the performance of future procedures in the patient and, in some<a href="https://solaci.org/en/2016/10/14/how-to-make-radial-access-even-safer-with-minimum-effort/" title="Read more" >...</a>

recanalizacion de cto en vaso no responsable

Rechanneling a CTO in a Non-Infarct-Related Artery After Primary PCI: Yes or No?

Between 10% and 15% of patients admitted with ST-segment elevation myocardial infarction present concurrent coronary chronic total occlusion (CTO) in a non-infarct-related artery, which is associated with increased morbidity and mortality.   The EXPLORE (Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) trial evaluated whether patients admitted<a href="https://solaci.org/en/2016/10/12/rechanneling-a-cto-in-a-non-infarct-related-artery-after-primary-pci-yes-or-no/" title="Read more" >...</a>

balon liberador de paclitaxel eficacia a largo plazo

Paclitaxel Drug Coated Balloon in Femoral: Effective at Long Term?

In patients with symptomatic peripheral vascular disease, the paclitaxel coated balloon showed superior efficacy at 3 years compared to the conventional balloon, in addition to very good results at one year when tested in the real world outside strict trial inclusion/exclusion criteria.   Both the IN.PACT SFA trial and the IN.PACT SFA global registry showed<a href="https://solaci.org/en/2016/10/11/paclitaxel-drug-coated-balloon-in-femoral-effective-at-long-term/" title="Read more" >...</a>

Chile Sessions 2016

31th SOLACI Regional Sessions – 10° Southern Cone Region November 30th and December 1st, 2016 Puerto Varas – Chile

Percutaneous Device Closure of PVL: An Alternative to Surgery

Paravalvular Leak (PVL) occurs in 5 to 17% of patients undergoing surgical valve replacement. Percutaneous device closure of PVL represents an alternative to repeat surgery.   All centers in UK and Ireland performing percutaneous PVL closure delivered their data to the UK PVL registry. Data were analyzed for factors associated with mortality and major cardiovascular<a href="https://solaci.org/en/2016/10/06/percutaneous-device-closure-of-pvl-an-alternative-to-surgery/" title="Read more" >...</a>

Is It Safe to Discontinue Ticagrelor One Day Before CABG?

Courtesy of Dr. Agustín Vecchia. Nearly 10% of patients with acute coronary syndrome (ACS) require surgery. Managing periprocedural dual antiplatelet therapy (DAPT) in ACS patients is controversial and, to date, there are no randomized trials in this regard. Guidelines recommend ticagrelor discontinuation five days prior surgery and in the most emblematic work on this drug<a href="https://solaci.org/en/2016/10/05/is-it-safe-to-discontinue-ticagrelor-one-day-before-cabg/" title="Read more" >...</a>

enfermedad de múltiples vasos síndrome coronario agudo

ACS and Multivessel Disease: How to proceed

Gentileza del Dr. Javier Castro   In the daily practice, a high percentage of ST elevation myocardial infarction patients (STEMI) present multivessel disease (40-65%). This group of patients presents worse clinical evolution and higher mortality than patients with one culprit lesion.   When PCI is indicated to a patient with significant lesions in more than<a href="https://solaci.org/en/2016/10/03/acs-and-multivessel-disease-how-to-proceed/" title="Read more" >...</a>

left main